Thread by @MatthewHalma

🧵 Supplement #3 in Long COVID: N-Acetylcysteine (NAC)

Cheap, FDA-approved, widely available. And it may do something the other supplements don't: directly degrade the SARS-CoV-2 spike protein.

Evidence and mechanism below. 🔽

NAC is a precursor to glutathione, the master antioxidant.

In long COVID, oxidative stress is elevated, glutathione is depleted, and endothelial cells are generating excessive reactive oxygen species. NAC replenishes glutathione directly.

NAC and the spike protein — a hypothesis worth watching:

NAC's free thiol group can theoretically break disulfide bonds in the SARS-CoV-2 spike protein's receptor-binding domain. Whether this occurs meaningfully in vivo, at supplemental doses, against persistently expressed spike, is not yet established.

A 2025 meta-analysis found NAC binds to the SARS-CoV-2 Mpro catalytic site via computational docking: pubmed.ncbi.nlm.nih.gov/40418545/
This is computational and in vitro data only. The hypothesis is biologically plausible and worth investigating. Direct human evidence for NAC clearing spike protein does not exist.

A note on context: NAC has been heavily promoted in medical freedom and alternative health communities, usually with claims that significantly outrun the evidence.

"Augmented NAC" formulations are marketed as superior to plain NAC, using claims of some modifications to the molecule at a quantum level. There is no evidence for this having superior effects in vitro or in vivo outside of their marketing materials.

For plain NAC, the spike protein disruption hypothesis is biologically interesting, it is not an established treatment effect.

NAC and von Willebrand factor: the evidence:

Bellone et al. (2024), Yale School of Medicine, identified persistently elevated vWF and Factor VIII in PASC/long COVID patients, markers of endothelial damage and microclot formation.

pmc.ncbi.nlm.nih.gov/articles/PMC10…

NAC has thrombolytic properties, it breaks disulfide bonds connecting vWF monomers, potentially dissolving the microthrombi that may drive tissue hypoxia in long COVID.

The treatment evidence: Bellone & Santin (2025), Yale, Gynecologic Oncology Reports
pmc.ncbi.nlm.nih.gov/articles/PMC11…

* n=3 NAC users vs n=6 PASC controls (retrospective case series)

* NAC dose: 600–1200 mg twice daily

* All 3 NAC users showed improvement in dyspnea, brain fog, and fatigue

* vWF normalized in all 3 NAC users vs none of 6 controls (Fisher's p=0.0119)

* Small n. Retrospective. The vWF normalization is the objective anchor. These are preliminary results warranting prospective trials.

The RCT evidence: Li et al. (2025), medrxiv preprint — double-blind, placebo-controlled medrxiv.org/content/10.648…

Important caveat: this trial enrolled patients recovering from acute COVID-19 infection, not post-acute or long COVID patients specifically.

n=63 (32 NAC, 31 placebo), 6-month follow-up post-discharge

Primary outcome: St. George's Respiratory Questionnaire (SGRQ)

Result: NAC significantly accelerated improvement in SGRQ vs placebo.

Preprint only, not peer reviewed. Extrapolation to Long COVID or PACVS is indirect.

The lipid metabolism mechanism is more interesting than the spike protein hypothesis.

It is more mechanistically complete, and directly explains the cardinal symptom, fatigue and exercise intolerance via a chain we can actually measure: glutathione depletion → lipid peroxidation → impaired fatty acid oxidation → elevated lactate → post-exertional malaise.

The spike protein angle is speculative in vivo. The lipid metabolism angle has published metabolomics data and an RCT precedent.

The PASC lipid metabolism impairment, the evidence:

de Boer et al. (2022), American Journal of Respiratory and Critical Care Medicine: pubmed.ncbi.nlm.nih.gov/34665688/

During graded exercise tests in PASC patients, two things were measured simultaneously: → Higher arterial blood lactate accumulation vs controls → Lower fatty acid oxidation rates vs controls

Same workload. More lactate. Less fat burning. This is the metabolic signature of impaired beta-oxidation measured directly in PASC patients during exercise.

Confirmed at rest too, Guntur et al. (2022), Metabolites: ncbi.nlm.nih.gov/pmc/articles/P…
Untargeted plasma metabolomics in n=29 Long COVID, n=16 recovered COVID, n=30 healthy controls.

Top metabolites separating PASC from recovered: → Lactate and pyruvate (ranked #1 and #2) → Long-chain acylcarnitines (fatty acids stuck outside mitochondria) → Free fatty acids

Pathway analysis confirmed: fatty acid biosynthesis, activation, metabolism, and beta-oxidation all significantly altered. The mitochondria are failing to import and burn fat. At rest.

Why are the fatty acids stuck?

Acylcarnitines accumulate when fatty acids can't enter the mitochondria — the transport step requires carnitine (see ALCAR in this series) AND functioning beta-oxidation enzymes.

Those enzymes are highly sensitive to oxidative damage. In PASC, lipid peroxidation is significantly elevated in lymphocytes (PNAS 2025): pnas.org/doi/10.1073/pn…
Oxidative stress → lipid peroxidation → damaged beta-oxidation enzymes → fatty acids can't be burned → cells default to glycolysis → lactate accumulates → post-exertional malaise.

Where NAC fits in this chain:

Glutathione is the primary cellular defence against lipid peroxidation — specifically the glutathione peroxidase system, which neutralises lipid hydroperoxides before they damage fatty acid oxidation enzymes.

NAC replenishes glutathione directly. It's the rate-limiting precursor.

By restoring glutathione → reducing lipid peroxidation → protecting beta-oxidation enzymes → NAC theoretically restores the cell's ability to burn fat rather than defaulting to glycolysis.

The RCT proof of concept — AXA1125 (eClinicalMedicine 2023): ncbi.nlm.nih.gov/pmc/articles/P…

AXA1125 is a targeted amino acid formulation designed specifically to restore beta-oxidation in long COVID. Double-blind phase 2a RCT, UK.

→ Significant improvement in physical AND cognitive fatigue vs placebo at 4 weeks → Authors note high baseline mitochondrial dysfunction supports beta-oxidation as the pathophysiologic target

NAC targets the same pathway upstream — by protecting the enzymes rather than flooding the substrate. Cheaper, already available.

Additional NAC mechanisms in long COVID:

→ Reduces TNF-α and IL-6 — both chronically elevated in PASC
→ Mucolytic — breaks disulfide bonds in mucin networks, relevant to respiratory symptoms
→ Neuroprotective via CNS oxidative stress reduction — relevant to brain fog

→ CoViNAC meta-analysis (12 RCTs, n=1,125): NAC reduced COVID-19 mortality 41% (RR=0.59, acute-phase) pubmed.ncbi.nlm.nih.gov/40418545/

While the evidence is in COVID infection, it may be relevant to #LongCOVID

Typical dosing: 1.2–2.4g/day.

Well tolerated up to 3–4g/day. The sulphurous smell is the thiol group.

At opensourcemed.info we are studying the impact of NAC, alongside other metabolic ingredients, specifically in PACVS, the vaccine-associated form of this syndrome. Register your interest vitalscan4pacvs.com

For spike protein persistence data: doi.org/10.1186/s43094…

Next: #4 . L-Glutamine 🔽